Curaleaf Holdings approved as Clinical Registrant by Pennsylvania DoH » 08:0402/2102/21/20
Curaleaf Holdings has…
Curaleaf Holdings has been approved as a Clinical Registrant in Pennsylvania by the Commonwealth's Department of Health, Office of Medical Marijuana. Under this designation, the company will be permitted to open a cultivation and processing facility and up to six dispensaries, under the Commonwealth's medical marijuana research program. As a Clinical Registrant, Curaleaf will support research initiatives into the potential medical benefits of cannabis by providing medical cannabis, expertise and distribution to patients participating in studies.
|Over a week ago|
Cantor initiates 10 cannabis names, sees opportunity after sellofff » 07:3302/1402/14/20
TCNNF, GGBXF, MMNFF, GTBIF, CURLF, CRLBF, AYRSF, ACRGF, HRVSF, ITHUF
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Pablo Zuanic launched coverage of 10 U.S. multi-state cannabis operators, saying the stocks are attractively valued with solid underlying industry fundamentals. He rates at Overweight Cresco Labs (CRLBF) and Trulieve Cannabis (TCNNF) and rates at Underweight Green Growth Brands (GGBXF). The analyst is Neutral on the rest of the space, but adds he will "keep an open mind." The Neutral ratings are on MedMen (MMNFF), Green Thumb Industries (GTBIF), Curaleaf Holdings (CURLF), Cresco Labs (CRLBF), Ayr Strategies (AYRSF), Acreage Holdings (ACRGF), Harvest Health & Recreation (HRVSF) and iAnthus (ITHUF). The current regulatory environment in key large U.S. "restricted" states provides a unique opportunity for multi-state operations to build out assets with a limited pool of competitors and be in a position of strength when full legalization comes, Zuanic tells investors in a research note. The boom and bust seen in Canadian stocks has, "unwarrantedly," dragged down U.S. MSOs and "masked strong underlying growth trends," contends the analyst. He believes this creates an attractive investment opportunity in the U.S. space.
Curaleaf Holdings initiated with a Neutral at Cantor Fitzgerald » 16:1302/1302/13/20
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Pablo Zuanic initiated coverage of Curaleaf Holdings with a Neutral rating.
Curaleaf granted final license approval for cannabis dispensary in Ware, MA » 12:4602/0602/06/20
Curaleaf Holdings announced it has been granted final license approval by the Massachusetts Cannabis Control Commission to open an adult-use retail dispensary in Ware, Massachusetts. Curaleaf hopes to schedule post-final inspections soon in an effort to open the adult use location, which will be located at 124 West Street, by early March 2020. The company opened its first adult-use retail location in Oxford, Massachusetts in November 2019 and its second adult-use retail location in Provincetown, Massachusetts on January 29, 2020. The company also has a medical-only facility in Hanover, Massachusetts.
Curaleaf Holdings to open cannabis dispensary on Cape Cod, MA » 08:1201/2901/29/20
Curaleaf Holdings announced it will open Cape Cod's first adult-use retail dispensary on Wednesday, January 29, at noon. The retail store is located at 170 Commercial Street in the heart of Provincetown and will be open seven days a week. Normal hours of operation are 10am - 6 pm from Monday through Saturday and 10am - 5pm on Sunday during the winter and early spring. Curaleaf will expand its hours to 9am - 9pm during the upcoming summer season. A grand opening celebration is being planned for February 6 at 11 am.
|Over a month ago|
Curaleaf Holdings shareholders agree to further extend lock-up » 08:0401/2201/22/20
Curaleaf Holdings announced that all shareholders holding individually more than 1% of Curaleaf's shares outstanding and all Cura Partners shareholders have agreed to an amended lock-up agreement in connection with the anticipated closing of Curaleaf's acquisition of Select. After closing, approximately 62% or 326.7M of the company's outstanding shares will be subject to the extended lock-up agreements. As previously announced, the company's largest shareholders and the Select shareholders agreed to a lock-up release schedule that provided for a quarterly release of 15% of each participant's shares. The revised lock-up agreement provides that after the close of the acquisition only 5% of each participant's holding will be released on the last day of each calendar quarter starting with March 31.
Curaleaf Holdings provides update on three acquisitions » 08:0601/1701/17/20
Curaleaf Holdings provided updates on the acquisitions of Cura Partners, GR Companies and Alternative Therapies. Curaleaf and Select have satisfied all requirements for closing the proposed acquisition of Select by Curaleaf except for the license transfer in Oregon. Both parties are working with state regulators to acquire approval as soon as possible and expect to close no later than February 1. Curaleaf and Grassroots have each submitted certifications of substantial compliance under the HSR Antitrust Improvements Act of 1976 regarding the proposed acquisition of Grassroots. The transaction is expected to close in Spring of 2020. ATG has filed its application for change of control with the Massachusetts Cannabis Control Commission in relation to the transaction with Curaleaf. Curaleaf and ATG are working with regulators to secure approvals as soon as possible.
Curaleaf Holdings receives preliminary processing license in Utah » 08:0801/1401/14/20
Curaleaf Holdings announced that it has received preliminary approval for a processing license by the Utah Department of Agriculture and Food. The notice grants Curaleaf permission to begin the build out of its processing facility immediately, with final approval of Curaleaf's Tier 1 medical cannabis processing license imminent. This follows the UDAF's recently announced Notice of Intent to Award a medical pharmacy license to Curaleaf.
Curaleaf Holdings initiated with a Buy at Needham » 07:3012/0312/03/19
Needham analyst Matt…
Needham analyst Matt McGinley initiated coverage of Curaleaf Holdings with a Buy rating and $7.25 price target. The analyst expects the coming year to see the company transition from a period of acquisition and developmental investment to integration and operational growth, optimizing its dispensary assets in medical and adult-use legal markets across 19 states. McGinley further believes that Curaleaf can triple its revenue in 2020 while boosting its EBITDA from "modestly positive" to at least $225M.
|Over a quarter ago|
FBN Securities cannabis analysts to hold a dinner meeting » 15:1711/1411/14/19
Analysts hold a Cannabis…
Analysts hold a Cannabis Industry Dinner with Boris Jordan, Co-Founder & Executive Chairman of Curaleaf in New York on November 14 hosted by FBN Securities.